Zydus Lifesciences has informed that it enclosed a copy of press release dated March 21, 2023 titled ‘Zydus granted Orphan Drug Designation by the USFDA for ZYIL1 in treatment of patients with Cryopyrin Associated Periodic Syndrome (CAPS)’.
The above information is a part of company’s filings submitted to BSE.